Table 1. Demographics and clinical characteristics of the derivation and test cohorts.
| Derivation Cohort | Test Cohort | |||||
| All | Survivors | Non-survivors | All | Survivors | Non-survivors | |
| N | 355 | 314 | 41 | 182 | 158 | 24 |
| Mortality (%) | 11.5 | – | – | 13.2 | – | – |
| Median days to death | – | – | 3 | – | – | 4 |
| (IQR) | (2–12) | (2–6) | ||||
| Mean days to death ±SD | – | – | 7.5±8.5 | – | – | 4.6±4.2 |
| Median age years | 2.4 | 2.5 | 1.9 | 5.5 | 5.6 | 5.0 |
| (IQR) | (0.9–6.1) | (1.0–6.3) | (0.5–5.6) | (1.6–13.0)2 | (1.7–13.1) | (0.6–9.0) |
| Median PRISM score | 13 | 12 | 26 | 11 | 11 | 19 |
| (IQR)1 | (7–20) | (7–19) | (17–36) | (9–18) | (8–15) | (13–25)3 |
| # of males (%) | 207 (58) | 183 (58) | 24 (59) | 94 (52) | 81 (51) | 13 (54) |
| # of females (%) | 148 (42) | 131 (42) | 17 (41) | 88 (48) | 77 (49) | 11 (46) |
| # for race (%) | ||||||
| Caucasian | 266 (75) | 237 (75) | 29 (71) | 129 (71) | 112 (71) | 17 (71) |
| African American | 54 (15) | 48 (15) | 6 (15) | 20 (11) | 18 (11) | 2 (8) |
| Other | 18 (5) | 15 (5) | 3 (7) | 3 (2) | 1 (1) | 2 (8) |
| Unreported | 17 (5) | 14 (4) | 3 (7) | 30 (16)2 | 27 (17) | 3 (13) |
| # with gram (+) bacteria (%) | 97 (27) | 85 (27) | 12 (29) | 54 (30) | 46 (29) | 8 (33) |
| # with gram (−) bacteria (%) | 82 (23) | 73 (23) | 9 (22) | 39 (21) | 31 (20) | 8 (33) |
| # with viral infection (%) | 26 (7) | 22 (7) | 4 (10) | 9 (5) | 5 (3) | 4 (17) |
| # with fungal infection (%) | 9 (3) | 8 (3) | 1 (2) | 7 (4) | 7 (4) | 0 (0) |
| # with no organism isolated (%) | 144 (41) | 129 (41) | 15 (37) | 80 (44) | 75 (47) | 5 (21) |
| # with any co-morbidity (%) | 143 (40) | 127 (40) | 16 (39) | 69 (38) | 60 (38) | 9 (38) |
| # with malignancy (%) | 34 (10) | 31 (10) | 3 (7) | 16 (9) | 15 (9) | 1 (4) |
| # with immune suppression (%)4 | 29 (8) | 26 (8) | 3 (7) | 17 (9) | 13 (8) | 4 (17) |
1
Nineteen subjects (18 survivors and 1 non-survivor) in the test cohort did not have available PRISM scores.
2
p<0.05 vs. test cohort.
3
p<0.05 vs. respective survivors.
4
Refers to patients with immune suppression not related to cancer (for example, those receiving immune suppressive medication for solid organ or bone marrow transplantation, or those with a primary immune deficiency).